Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

0.9701 -0.0299 (-2.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
Which stocks have an unusual volume on Monday?
In today's session, there are stocks attracting attention with their unusual volume. Let's take a closer look. 
Via Chartmill
SciSparc Shares Are Soaring Monday: What's Going On?
SciSparc Ltd (NASDAQ:SPRC) shares are ripping higher Monday after the company announced that its collaboration with Clearmind Medicine Inc (NASDAQ:CMND) led to a patent application for psychedelic... 
Via Benzinga
Topics Intellectual Property
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
SciSparc teams up with Clearmind Medicine on innovative therapies for binge behaviors and secures FDA approval for a Tourette Syndrome Phase 2b trial. 
Via Benzinga
Why Is Penny Stock Clearmind Gaining Today?
Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder. 
Via Benzinga
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
CMND Stock Earnings: Clearmind Medicine Reported Results for Q2 2024
Clearmind Medicine just reported results for the second quarter of 2024. 
Via InvestorPlace
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Clearmind Medicine filed an international patent for a treatment that aims to enhance addiction treatment safety and efficacy. 
Via Benzinga
Topics Intellectual Property
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes
Clearmind Medicine secures a U.S. patent for its MEAI-based binge behavior treatment, marking a significant advancement in addressing Alcohol Use Disorder. 
Via Benzinga
Topics Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns! 
Via InvestorPlace
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
 
Via Benzinga
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
 
Via Benzinga
Why Is SciSparc (SPRC) Stock Up 25% Today?
SciSparc stock is up on Tuesday as SPRC investors learn of the company filing a new patent covering its weight loss treatment. 
Via InvestorPlace
Topics Intellectual Property
Dow Jumps 400 Points; US Retail Sales Flat For June
 
Via Benzinga
Topics Stocks
Why Psychedelic-Pharma Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine shares are trading higher Friday after the company announced advancement in its proprietary MEAI-based binge behavior regulator program through the granting of patent approval in... 
Via Benzinga
Topics Intellectual Property
Day Trading My Way From Red To Green
I set daily profit goals and max loss limits to manage my risk. My daily goal is $5,000, and I cap my daily loss at the same amount. 
Via Talk Markets
What's Going On With Clearmind Medicine Stock Tuesday?
Clearmind said its alcohol substitute was granted patents in the U.S., India and Europe. The company also highlighted that the no/low alcohol category is forecasted to grow at a volume CAGR of more... 
Via Benzinga
Topics Intellectual Property
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Why Clearmind Medicine Stock Is Moving Higher
Clearmind Medicine shares are up Tuesday after the company announced it signed an exclusive patent licensing agreement with Yissum Research Development. 
Via Benzinga
Topics Intellectual Property
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
 
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
 
Via Benzinga
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
 
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
 
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
 
Via Benzinga
Topics Economy
Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year increase in FY23 EPS results. 
Via Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
 
Via Benzinga
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
 
Via Benzinga
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
 
Via Benzinga
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection. 
Via Benzinga
Topics Intellectual Property
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.